Blincyto® (blinatumomab) – New indication
June 14, 2024 - Amgen announced the FDA approval of Blincyto (blinatumomab), for the treatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase of multiphase chemotherapy in adult and pediatric patients one month and older.
Top